Trials / Completed
CompletedNCT02168309
Oral Nifedipine Versus Oral Labetalol
Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Cedars-Sinai Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study's aim is to determine whether oral extended release nifedipine is superior to oral labetolol for the management of postpartum severe hypertension, specifically time to achieve goal blood pressure, and shortening hospital stay. Our hypothesis is that oral extended release nifedipine is superior to oral labetolol for achieving goal blood pressure in the postpartum period.
Detailed description
Hypertension complicating pregnancy is common and, when uncontrolled, can have devastating consequences. While the true incidence of postpartum hypertension is unknown, blood pressure (BP) is known to initially decrease 48 hours following delivery then peak on postpartum days 3-6, likely 45 from the mobilization of interstitial fluids following parturition. The American College of Obstetricians and Gynecologists (ACOG) recommends medical treatment of persistent postpartum hypertension, defined as systolic BP (SBP) ≥150 mmHg or diastolic BP (DBP) ≥100 mmHg, on two or more occasions 4-6 hours apart. Prior studies compared intravenous medications to intramuscular and immediate-release oral 50 medications in the treatment of postpartum hypertension. However, oral labetalol and oral extended release nifedipine are the most commonly used medications for post- partum hypertension, and their efficacy has not been directly compared. Our aim was to determine whether oral labetalol is associated with a shorter time to BP control compared to oral extended release nifedipine for management of persistent 55 postpartum hypertension. Our primary outcome was time to sustained BP control defined as the absence of severe hypertension (SBP ≥160 mmHg or DBP ≥105 mmHg) for at least 12 hours. Secondary outcomes included postpartum length of stay, need for increased dosing, need for additional oral antihypertensive agents, and patient-reported side effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Labetalol | Titrate up for blood pressure control |
| DRUG | Nifedipine | Titrate up to achieve blood pressure control |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-06-01
- Completion
- 2016-05-01
- First posted
- 2014-06-20
- Last updated
- 2017-12-13
- Results posted
- 2017-12-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02168309. Inclusion in this directory is not an endorsement.